Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wook, I think that one got ruled out of bounds.
LOL. I believe they refer to the game tennis.
Chart is like watching a ping pong game.
they love that one...
Bashers use a variety of techniques. The most obvious is to fabricate derogatory information. Another is to flood a message board with sheer nonsense to intentionally disrupt the discussion and drive new traffic, i.e., potential investors, away from the site.
Apparently they've discovered that the only way to drive traffic to their site is through the spectacle of assiduous inanity.
What they actually mean is "street shill indicator" bounce.
Err...but you only post on the PPHM board and not on any of the boards belonging to "people who are actually trying to fight cancer?" Sounds a little fishy. Maybe you just don't like the criticism here of a certain second rate blogger.
That seems like quite an increase given that NASDAQ lists current total institutional ownership at 26,283,501 shares. Looks like the decimal places may be off by a million. Of course, that's from NASDAQ data as of 12/31/13. i.e, State Street 1,780,186 shares held.
Sour grapes. Somebody got his panties in a twist over my earlier comment on the "biotech windbag." I guess the truth hurts.
SK's delivery - often unfairly criticized, imo - is usually dry, monotone, and hyper-technical, but from the audio alone with no visual cues from body language, he clearly was having trouble containing his excitement. It was like he hit a straight flush in a big pot and immediately jumped for his chips out of turn. I have tremendous respect for SK as a scientist, but man do I want to play poker with this guy!
Apparently the guy tries to grind out a living by uncritically parroting the most scandalous of rumors in hopes that the controversy will drive some traffic toward his blog. Typically there's no merit to his conclusions, but he is a reliable indicator that a vested interest in trying to push misinformation onto the street.
Great points, CP. IMO, the price action early this week attracted day traders and possibly kicked in some algos or HFT, which would tend to add some volatility. But complaining about $1.80 to $2.40 in one week is like crying with a loaf of bread under each arm, so great weekend to all!
Desperate ravings by AF are typically a bullish indicator.
where is the AF article? can someone cite a reference?
And we don't know how their billing milestones are structured, so is it reasonable to expect them to be distributed evenly on a quarterly basis?
I'm reading the PR to say that they expect volume to increase for the year.
The quarterly variance in contract revenue appears to be inconsequential. Pointing again to PR:
The reduction in Avid revenues is clearly detailed in the PR:
$3.00!!!
$2.98! AH <EOM>
Okay...The Street has PPHM listed at #2 for the day.
Sorry..49% gain. Can't keep up.
45% Gain. How come PPHM is not on any of the major lists of today's gainers, including NASDAQ?
Hope whoever went to lunch with a short position picked up some Tums on the way back.
LONDON, March 5, 2014 /PRNewswire/ --
More buyers than sellers. Other that that....something.
9.3 MM shares in first hour.
Rock 'em Sock 'em Robot time of day.
Bye bye $2.00.....Series E @ premium of $33.00 is also intriguing.
Probably some gaps to be filled back to $70. Check the historical charts.
$1.98 AH. Suggest the most appropriate analysis of extended trading is: Hmmm...
Ranking ahead of Genetech (491), Celgene (492), and Endo (498).
Very well indeed!
Series E trading at a premium: $25.85
Really no synergies imo.
Hopefully by then we've all cashed out of PPHM with a huge gain which we can invest in "safe" CDs at 36% APY.
Did Abbvie turn down King's "lofty" demands, or did the CSM Phase II errors induce them to suspend talks?
On the other hand, is there anything inherently negative? Generex is nano-cap at present, but Joseph Rubinfeld is on their Scientific Advisory Board, and he's without question a heavy hitter in biopharm.
Generex? AF is going to blow a gasket! LOL
Unfortunately, unlike nearly every other Western Democracy, we do not observe the English Rule where the loser pays all legal fees. However, I believe the Judge might have discretion to compel the plaintiff to pick up the tab as a sanction for abusive process.